Role of oncogenes in resistance and killing by cancer therapeutic agents

Current Opinion in Oncology

Volumn 9, Issue 1, 1997, Pages 79-87

  El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; DNA METHYLTRANSFERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; METALLOTHIONEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

CANCER CHEMOTHERAPY; CELL DEATH; CELL KILLING; CELL MEMBRANE RESISTANCE; CHROMOSOME ABERRATION; DETOXIFICATION; DNA REPAIR; ENZYME INACTIVATION; HUMAN; MEMBRANE TRANSPORT; ONCOGENE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW;

EID: 0030998763     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199701000-00013     Document Type: Review

References (122)

1. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-159.
2. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD: Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995, 55:5342-5347.
3. Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA: Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 1994, 54:1649-1652.
4. Giaccone G, Van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans A-M C, Flens MJ, Scheper RJ, Pinedo HM: MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung. Int J Cancer 1996, 66:760-767.
5. Schadendorf D, Makki A, Stahr C, Van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM: Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995, 147:1545-1552.
6. Murase M, Kodera Y, Kondo K, Sekiguchi H, Fujiwara M, Kasai Y, Akiyama S, Ito K, Takagi H: Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. J Surg Oncol 1996, 61:223-229.
7. Endo K, Maehara Y, Ichiyoshi Y, Kusomoto T, Sakaguchi Y, Ohno S, Sugimachi K: Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 1996, 77:1681-1687.
8. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G: Role of the mdr-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993, 150:1544-1547.
9. Faulkner Pulsford JF, Sargent JM, Elgie AW, Williamson CJ, Taylor CG: Comparison of P-glycoprotein expression with in-vitro drug sensitivity in fresh blast cells from acute myeloid leukaemia patients. Br J Biomed Sci 1995, 52:188-194.
10. Schadendorf D, Herfordt R, Czarnetzki BM: P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 1995, 132:551-555.
11. Arvelo F, Poupon MF, Bichat F, Grossin F, Bourgeois Y, Jacrot M, Bastian G, Le Chevalier T: Adding a reverser (Verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Eur J Cancer 1995, 31A:1862-1868.
12. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13:1995-2004. Report of a clinical trial involving the use of dexverapamil to inhibit MDR1 P-glycoprotein function in 154 patients with drug-resistant advanced non-Hodgkin's lymphoma and Hodgkin's disease. The response rate was 12% in nonHodgkin's lymphoma and 20% in Hodgkin's disease. The presence of increased MDR1 expression correlated with a higher response rate to dexvarapamil. It was concluded that additional mechanisms contribute to drug resistance in advanced lymphoma and that perhaps earlier intervention with dexverapamil may have more efficacy.
13. Schwarzenberger P, Spence S, Lohrey N, Kmiecik T, Longo DL, Murphy WJ, Ruscetti FW, Keller JR: Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line: in vivo model for genetically transferred chemoprotection. Blood 1996, 87:2723-2731. Human hematopoietic progenitor cells were infected by MDR1-expressing retrovirus and transplanted into severe combined immunodeficient mice. These cells became resistant to taxol in vitro. Treatment of mice with taxol resulted in a 15-fold decrease in human DNA (using a polymerase chain reaction-based method to specifically detect human DNA) in severe combined immunodeficient mice transplanted with uninfected cells, whereas no change occurred in human DNA content in retrovirusinfected progenitors transplanted in the mice.
14. Blagosklonny MV, El-Deiry WS: In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 1996, 67:386-392. These in vitro studies highlighted the potential of p53-expressing adenovirus to treat multidrug-resistant cancer cells. The use of p21 immunostaining as evidence of p53 infectivity was demonstrated and was suggested as a way to track p53 function in vivo, where p53 staining is often not helpful (at least 75% of mutated p53 in human tumors is stabilized and therefore already overexpressed but transcriptionally inactive). It was also demonstrated that p53-expressing adenovirus may confer synergy to some but not to all chemotherapeutic drugs.
15. Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC: The role of glutathione in drug resistance. Cancer Treat Rev 1990, 17A:45-50.
16. Britten RA, Green JA, Wareenius HM: Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Rad Oncol 1992, 24:527-531.
17. Mestdagh N, Pommery N, Saucier J-M, Hecquet B, Fournier C, Slomianny C, Teissier E, Henichart J-P: Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes. Anticancer Res 1994, 14:869-874.
18. Inoue T, Ishida T, Sugio K, Maehara Y, Sugimachi K: Glutathione S transferase π is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 1995, 62:223-227.
19. Mousseau M, Chauvin C, Nissou M-F, Chaffanet M, Plantaz D, Pasquier B, Schaerer R, Benabid A: A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumors. Eur J Cancer 1993, 29A:753-759.
20. Kelley SL, Basu A, Leicher BA, Hacker MP, Hamer DH, Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988, 241:1815-1818.
21. Lohrer H, Robson T. Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 1989, 10:2279-2284.
22. Kama B, Lohrer H, Kann M, Herrlich P: Overexpressed human metallothionein II gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sci U S A 1990, 87:2710-2714.
23. Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG: Metallothionein in testicular germ cell tumors and drug resistance. Cancer 1993, 72:3029-3035.
24. Okamoto K, Toyokuni S, Kim WJ, Ogawa O, Kakehi Y, Arao S, Hiai H, Yoshida O: Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Int J Cancer 1996, 65:437-441.
25. Ferrando AA, Velasco G, Campo E, Lopez-Otin C: Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res 1996, 56:1746-1750. Human bleomycin hydrolase, a proteolytic enzyme, was cloned. Its expression levels were high in head and neck tumors and low or undetectable in lymphoma. It has not yet been demonstrated that Overexpression of the cDNA could confer bleomycin or other drug resistance.
26. Bertino JR, Romanini A, Dicker A, Colkendandt M, Lin JJ, Schweitzer I: Resistance to MTX: experimental and clinical. In Drug Resistance: Mechanisms and Reversal. Edited by Mihich E. Rome: John Libbey CIC: 1990:33-40.
27. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09. J Natl Cancer Inst 1996, 88:259-269.
28. 6-methylguanine-DNA methyl transferase in human normal and tumor tissue from brain. Cancer Res 1991, 51:4131-4134.
29. Day RS, Ziolkowski CHJ, Scudiero DA, Meyer SA, Mattern MR: Human tumor cell strains defective in the repair of alkylation damage. Carcinogenesis 1990, 11:21-32.
30. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis 1992, 13:1503-1507.
31. 6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol Carcinogenesis 1991, 4:482-488.
32. 6-methylguanine-DNA methyltransferase cDNA confers resistance of Mer- HeLa MR cells to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea. Carcinogenesis 1995, 16:2271-2274.
33. Nagane M, Shibui S, Oyama H, Asai A, Kuchino Y, Nomura K: Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma. Surg Neurol 1995, 44:462-470.
34. Potmesil M, Hsiang YH, Liu LF, Wu HY, Traganos F, Bank B, Silber R: DNA topoisomerase II as a potential factor in drug resistance of human malignancies. Natl Cancer Inst Monogr 1987, 4:105-109.
35. Yarbro JW: The scientific basis of cancer chemotherapy. In The Chemotherapy Sourcebook. Edited by Perry MC. Baltimore: Williams and Wilkms; 1992:7-8.
36. Eijdems EW, de Haas M, Timmerman AJ, Van der Schans GP, Kamst E, de Nooij J, Astaldi Ricotti GC, Borst P, Baas F: Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer 1995, 71:40-47.
37. Wasserman RA, Wang JC: Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res 1994, 54:1795-1800.
38. Hsiung Y, Jannatipour M, Rose A, McMahon J, Duncan D, Nitiss JL: Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res 1996, 56:91-99.
39. Nitiss JL, Vilalta PM, Wu H, McMahon J: Mutations in the gyrB domain of eucaryotic topoismerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol Pharmacol 1994, 46:773-777.
40. Hashimoto S, Danks MK, Chatterjee S, Beck WT, Berger NA: A novel point mutation in the 3′ flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents. Oncol Res 1995, 7:21-29.
41. McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA: Topoisomerase II alpha expression in acute myeloid leukemia and its relationship to clinical outcome. Leukemia 1994, 8:1498-1502.
42. Feldhoff PW, Mirski SE, Cole SP, Sullivan DM: Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994, 54:756-762.
43. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P: An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 1993, 90:6424-6428.
44. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994, 54:4308-4312.
45. WAF1/CIP1 and the control of cell proliferation. In Cell Cycle Control and Apoptosis in Malignant Disesse. Edited by Thomas NSB. Oxford: Bios Scientific Publishers; 1996:55-75.
46. WAF1/CIP1-/- human cancer cells. Cancer Res 1996, 56:2250-2255. Absence of the cell cycle inhibitor p21 was shown to contribute to a DNA repair deficiency. This deficiency led to increased sensitivity to ultraviolet radiation. It was suggested that agents that can disrupt the interaction between the proliferating cell nuclear antigen and p21 may alter the sensitivity of cancer cells to DNA-damaging chemotherapeutic drugs.
47. Waldman T, Lengauer C, Kinzler KW, Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996, 381:713-716. It was shown that the cyclin-dependent kinase (CDK)-inhibitor p21 is required for coordination of the S- and M-phases of the cell cycle. Treatment of p21-deficient cells with DNA damaging drugs resulted in G2-arrest and additional rounds of DNA replication without evidence of mitotic cell division. These DNA-damaged polyploid p21-deficient cells died by an apoptotic mechanism. It was suggested that drugs that cause uncoupling of the S- and M-phases of the cell cycle represent many of the effective antineoplastic drugs and that more drugs that act by this mechanism should be sought.
48. Wang J, Walsh K: Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 1996, 273:359-361.
49. Stone S, Dayananth P, Kamb A: Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996, 56:3199-3202. Induction of the CDK-inhibitor and tumor suppressor p16 by an exogenous promoter led to a reversible cell cycle arrest and was shown to significantly protect a melanoma cell line to the cytotoxic effects of methotrexate, vanblastine, and cisplatin. Additional work is needed to determine whether such a strategy can be employed in-vivo, because at present, the physiologic signals that induce p16 are unknown. It also remains a mystery as to why a tumor suppressor such as p16 would protect cancer cells from apoptosis induced by chemotherapeutic drugs, because apoptosis can occur from any part of the cell cycle.
50. Fearon ER: Oncogenes and tumor suppressor genes. In Clinical Oncology. Edited by Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. New York: Churchill Livingstone; 1995:11-40.
51. Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C, Gazdar AF: Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with Her-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993, 85:897-901.
52. Tsai C-M, Chang K-T, Wu L-H, Chen J-Y, Gazdar AF, Mitsudomi T, Chen M-H, Perng R-P: Correlations between intrinsic chemoresistance and Her-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996, 56:206-209.
53. neu levels in Her-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 1995, 87:682-684.
54. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to Her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
55. neu expressing non-small cell lung cancer cells. Cancer Res 1996, 56:1068-1074. A selective inhibitor of Her-2/neu tyrosine kinase activity, tyrphostin AG825. enhanced the chemosensitivity of NSCLC cells that overexpressed Her-2/neu (but not cells that did not overexpress Her-2/neu). A good rationale was provided for the use of Her-2/neu antagonists in vivo and in clinical trials.
56. Zhang L, Hung M-C: Sensitization of Her-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996, 12:571-576. Emodin, a Her-2/neu tyrosine kinase inhibitor, decreased phosphorylation of Her-2/neu and preferentially suppressed proliferation of Her-2/neu overexpressing NSCLC cells. Emodin sensitized the lung cancer cells to the cytotoxic effects of cisplatin, doxorubicin, and etoposide.
57. Tsujimoto Y, Cossman J, Jaffe E, Croce C: Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443.
58. Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986, 47:19-28.
59. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
60. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995, 11:1217-1228.
61. Silverstrini R, Veneroni S, Daidone MG, Benini E, Borscchi P: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer in patients. J Natl Cancer Inst 1994, 86:499-504.
62. Kamesaki S, Kamesaki H, Jorgenson TJ, Tanizawa A, Pommier Y, Cossman J: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993, 53:4251-4256.
63. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995, 55:3902-3907. Estrogen receptor positive (but not receptor negative) breast cancer cells upregulated bcl-2 mRNA and protein expression following estrogen exposure. Estrogen depletion, antiestrogen treatment, or bcl-2 antisense treatment enhanced chemosensitivity of estrogen receptor positive breast cancer cells in vitro.
64. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994, 54:3253-3259.
65. Lasorella A, Iavarone A, Israel MA: Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 1995, 55:4711-4716.
66. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G: Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995, 9:1191-1198.
67. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA: Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993, 53:3321-3326.
68. Reeve JG, Xiong J, Morgan J, Bleehen NM: Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 1996, 73:1193-1200.
69. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE: Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth and Diff 1995, 6:1395-1403.
70. Frankfurt OS, Seckinger D, Sugarbaker EV: Pleitropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int J Cancer 1994, 59:217-224.
71. Wu GS, El-Deiry WS: Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996, 2:623-633.
72. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res and Dev 1994, 4:71-79.
73. Keith FJ, Bradbury DA, Zhu Y-M, Russell NH: Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to ara-C. Leukemia 1995, 9:131-138.
74. Haldar S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996, 56:1253-1255. Treatment of bcl-2 expressing LNCaP prostate cancer cells with taxol induced apoptosis that was correlated with bcl-2 phosphorylation. No apoptosis was observed following taxol treatment of bcl-2-negative DU145 prostate cancer cells. It was suggested that phosphorylated bcl-2 may contribute to cell death by interacting less efficiently with the death promoting bax protein. Studies of the effects of phosphorylation mutants of bcl-2 on bcl-2:bax heterodimerization and taxol chemosensitivity in prostate cancer (and other human cancer cells) are needed to test the hypotheses generated by these studies.
75. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res 1996, 56:1851-1854.
76. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.
77. S-expressing adenovirus induced apoptosis even in the absence of chemotherapy.
78. L can confer a multidrug resistance phenotype. Blood 1995, 86:1903-1910.
79. Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapek CA, Kufe D: Overexpression of bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Diff 1995, 6:363-370.
80. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene. Science 1986, 233:212-214
81. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497.
82. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994, 83:1179-1187
83. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994, 83:2038-2044.
84. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to muliple anticancer agents. Blood 1995, 86:1148-1158.
85. Gewirtz AM: Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia. Leuk Lymphoma 1993, 11:131-137.
86. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B: Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1994, 91:4504-4508.
87. Smetsers TF, Van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ: Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 1995, 9:118-130.
88. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martial P: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 1995, 86:3891-3896.
89. Velculescu VE, El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996, 42:858-868.
90. Ruley HE: p53 and response to chemotherapy and radiotherapy. In Important Advances in Oncology 1996. Edited by Devita VT Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven; 1996:37-56.
91. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
92. Wu GS, El-Deiry WS: p53 and chemosensitivity. Nature Med 1996, 2:255-256.
93. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, Andreotti PE: Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochim Biophys Res Comm 1994, 199:264-270.
94. Slickenmyer WJ, Nelson WG, Slebos RJ, Kastan MB: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993, 53:4164-4168.
95. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994, 54:5824-5830.
96. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55:1649-1654.
97. Chresta CM, Masters JR, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 1996, 56:1834-1841. The presence of functional p53 and high bax:bcl-2 ratio was found in drug-sensitive (curable) testicular cancer cells but not in bladder cancer control cells. No change in the bax:bcl-2 ratio was observed following treatment of cells with DNA damaging agents. The absence of bcl-2 and the predisposition to undergo (p53-dependent) apoptosis rather than G1 arrest following DNA damage were properties of the testicular cancer cells felt to correlate well with their chemosensitivity.
98. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K: The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin and Oncol 1996, 122:360-365.
99. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996, 56:689-693. Analysis of p53 status in 33 ovarian cancer (International Federation of Gynecology and Obstetrics stage III and IV) at debulking correlated well with subsequent response to cisplatin-based chemotherapy.
100. Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP: The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995, 64:37-46.
101. Yang B, Eshleman JR, Berger NA, Markowitz SD: Wild-type p53 protein potentiates cytotoxicity of therapreutic agents in human colon cancer cells. Clin Cancer Res 1996, 2:1649-1657.
102. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ Jr: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994, 9:3743-3751.
103. Thomas A, El Rouby S, Red JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055-1062.
104. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Red JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56:556-562.
105. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994, 54:2287-2291.
106. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996, 2:1665-1671. Gene transfer using p53-expressing adenovirus in SW620 colorectal cancer cells sensitized the cells to the cytotoxic effects of ionizing radiation in vitro and in vivo More apoptosis (by TUNEL assay) occurred in subcutaneous xenografts treated with p53-adenovirus and irradiated versus either irradiation alone or p53-adenovirus alone.
107. De Oca Luna RM, Wagner DS, Lozano G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
108. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
109. Kondo S, Barnett GH, Hara H, Morimura T, Tekeuchi J: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 1995, 10:2001-2006.
110. Sklar MD, Prochownik EV: Modulation of cisplatinum resistance in friend erythroleukemia cells by c-myc. Cancer Res 1991, 51:2118-2123.
111. Niimi S, Nagakawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M, Saijo N: Resistance to drugs in NIH3T3 cells transfected with c-myc and c-Ha-ras genes. Br J Cancer 1991, 63:237-241.
112. Sanchez-Prieto R, Vargas JA, Carnero A, Marchetti E, Romero J, Duraritez A, Lacal JC, Cajal SRY: Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. Int J Cancer 1995, 60:235-243.
113. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O: Enhancement of sensitivity of urinary baldder tumour cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994, 74:2546-2554.
114. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE: Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 1996, 73:610-614.
115. McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, Muschel RJ: Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 1990, 50:97-102.
116. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 1996, 56:1727-1730. Because activated H-ras is a tumor-specific property and because farnesylation is required for H-ras activity, it was predicted that inhibition of farnesylation may offer a therapeutic advantage particularly when combined with radiotherapy. It is known that activated H-ras makes cells more radioresistant. The inhibition of farnesylation increased radiosensitivity of H-ras transformed cells but did not affect control cells. Although H-ras mutations are not frequent in human tumors, the approach may be amenable to the therapy of mutant K-ras-expressing tumors, particularly when combined with radiotherapy.
117. Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D, Myers CE: Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 1996, 49:972-979.
118. Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D: Cis-dichloroplatinum (II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res 1992, 52:878-882.
119. Moffat GJ, McLaren AW, Wolf CR: Involvement of jun and fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem 1994, 269:16397-16402.
120. Yamazaki H, Schneider E, Myers CE, Sinha BK: Oncogene overexpression and de novo drug-resistance in human prostate cancer cells. Biochim Biophys Acta 1994, 1226:89-96.
121. Bhushan A, Abramson R, Chiu JF, Tritton TR: Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharm 1992, 42:69-74.
122. Scanlon KJ, Ishida H, Kashani-Sabet M: Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci U S A 1994, 91:11123-11127.